Breaking News Instant updates and real-time market news.

NVS

Novartis

$88.00

3.54 (4.19%)

, BIIB

Biogen

$228.00

-1.05 (-0.46%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30

ICER says Zolgensma price falls within upper bound of benchmark range

The Institute for Clinical and Economic Review said in a statement, "Zolgensma is dramatically transforming the lives of families affected by this devastating disease, and given the new efficacy data for the presymptomatic population, the price announced today falls within the upper bound of ICER's value-based price benchmark range. Insurers were going to cover Zolgensma no matter the price, and Novartis has spoken publicly about considering prices that approached $5 million. It is a positive outcome for patients and the entire health system that Novartis instead chose to price Zolgensma at a level that more fairly aligns with the benefits for these children and their families." Novartis (NVS) announced today that the FDA approved Zolgensma to treat pediatric patients less than two years of age with spinal muscular atrophy. Shares of Biogen (BIIB) and Ionis Pharmaceuticals (IONS) are trading lower following the approval of Zolgensma. Reference Link

NVS

Novartis

$88.00

3.54 (4.19%)

BIIB

Biogen

$228.00

-1.05 (-0.46%)

IONS

Ionis Pharmaceuticals

$65.44

-1.69 (-2.52%)

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

NVS Novartis
$88.00

3.54 (4.19%)

05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
BIIB Biogen
$228.00

-1.05 (-0.46%)

05/20/19
FBCO
05/20/19
INITIATION
FBCO
Underperform
Biogen initiated with an Underperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Biogen with an Underperform rating and $198 price target, saying that "life beyond aducanumab will likely remain challenging for Biogen" with the company's core base business "likely to decline in the near term with a weak pipeline that will not likely be able to yield revenue and earnings growth." While Seigerman said that Biogen's MS business is stable, he noted that headwinds are mounting.
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/23/19
05/23/19
INITIATION
Target $231

Neutral
Biogen initiated with a Neutral at Wedbush
As previously reported, Wedbush analyst Laura Chico started Biogen with a Neutral rating and a $231 price target. The analyst says the company is "at a crossroads" as it looks to move on from its recent aducanumab Alzheimer's disease setback, noting that few of its early-stage pipeline assets appear to be positioned to make a near-term impact on its top line. Chico further warns that inter partes review of Biogen's Tecfidera patent could lead to generic competition sooner than expected.
05/22/19
WEDB
05/22/19
INITIATION
Target $231
WEDB
Neutral
Biogen initiated with a Neutral at Wedbush
Wedbush analyst Laura Chico started Biogen with a Neutral rating and $231 price target.
IONS Ionis Pharmaceuticals
$65.44

-1.69 (-2.52%)

05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $75
PIPR
Neutral
Ionis Pharmaceuticals shares 'more interesting on pullback', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Neutral rating and $75 price target on Ionis Pharmaceuticals after its Q1 results with Spinraza royalties and Tegsedi sales seen "in line with expectations". The analyst believes that the company's pipeline is maturing as it gets ready to launch Waylivra in Europe next quarter and also sees its Huntington's OLE continuing to progress. Van Buren contends that Ionis Pharmaceuticals stock is "becoming more interesting" from a long term investment perspective given the recent pullback in price.
05/24/19
PIPR
05/24/19
NO CHANGE
Target $75
PIPR
Neutral
Piper 'incrementally more positive' on Ionis after management meetings
Piper Jaffray analyst Tyler Van Buren says he's "incrementally more positive" on shares of Ionis Pharmaceuticals after hosting meetings with management. The company is in a "healthy and very rare" financial position relative to other mid-cap biotechs with ongoing profitability, $2.3B in cash, and nearly $400M in "durable" annual research and development revenues that offset R&D expenses, Van Buren tells investors in a research note. This provides Ionis valuation support, long-term stability, and allows for value creation on a "step-function basis" as each additional clinical asset becomes de-risked, adds the analyst. Van Buren keeps a Neutral rating on the shares with a $75 price target.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $142
PIPR
Overweight
Piper more confident in estimates for Alnylam's Onpattro after doctor survey
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $142 price target after surveying 16 physicians treating 490 hereditary transthyretin amyloidosis patients with polyneuropathy. Doctors have a "clear preference" for Alnylam's Onpattro over Onpattro and Ionis Pharmaceuticals' (IONS) Tegsedi, with efficacy, safety, and experience being cited, Tenthoff tells investors in a research note. Roughly two-thirds of existing and new gene silencer patients are prescribed Onpattro, says the analyst. Based on the survey results, the analyst is increasingly confident in his 2019 Onpattro sales estimates of $127M.

TODAY'S FREE FLY STORIES

PCMI

PCM, Inc.

$34.67

10.315 (42.36%)

, NSIT

Insight Enterprises

$56.89

0.7 (1.25%)

13:13
06/24/19
06/24
13:13
06/24/19
13:13
Recommendations
PCM, Inc., Insight Enterprises analyst commentary  »

Insight Enterprises price…

PCMI

PCM, Inc.

$34.67

10.315 (42.36%)

NSIT

Insight Enterprises

$56.89

0.7 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

NBL

Noble Energy

$21.32

-0.24 (-1.11%)

, OXY

Occidental Petroleum

$50.09

-0.53 (-1.05%)

13:07
06/24/19
06/24
13:07
06/24/19
13:07
Periodicals
U.S. natural gas prices plummet in June, Forbes says »

According to Jude…

NBL

Noble Energy

$21.32

-0.24 (-1.11%)

OXY

Occidental Petroleum

$50.09

-0.53 (-1.05%)

EOG

EOG Resources

$90.84

-1.57 (-1.70%)

DVN

Devon Energy

$27.93

-0.31 (-1.10%)

APA

Apache

$29.14

-0.52 (-1.75%)

CHK

Chesapeake

$1.89

-0.055 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 02

    Aug

  • 27

    Aug

  • 13

    Nov

D

Dominion

$79.35

1.01 (1.29%)

13:05
06/24/19
06/24
13:05
06/24/19
13:05
Options
Dominion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDS

Aridis Pharmaceuticals

$9.65

-0.55 (-5.39%)

13:04
06/24/19
06/24
13:04
06/24/19
13:04
Hot Stocks
Aridis' treatment of lung infections in CF patients granted orphan designation »

Aridis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELF

e.l.f. Beauty

$13.37

0.3 (2.30%)

, COTY

Coty

$13.09

-0.12 (-0.91%)

13:02
06/24/19
06/24
13:02
06/24/19
13:02
On The Fly
Ulta, Sally Beauty slide after Amazon announces Professional Beauty Store »

Shares of Ulta Beauty…

ELF

e.l.f. Beauty

$13.37

0.3 (2.30%)

COTY

Coty

$13.09

-0.12 (-0.91%)

REV

Revlon

$21.48

-0.65 (-2.94%)

EL

Estee Lauder

$183.51

2.21 (1.22%)

AMZN

Amazon.com

$1,907.03

-3.39 (-0.18%)

SBH

Sally Beauty

$12.83

-1.96 (-13.25%)

ULTA

Ulta Beauty

$342.74

-13.03 (-3.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 01

    Jul

  • 09

    Jul

  • 10

    Jul

  • 19

    Aug

  • 29

    Aug

MCRB

Seres Therapeutics

$2.99

0.31 (11.57%)

, PSEC

Prospect Capital

$6.62

0.02 (0.30%)

13:01
06/24/19
06/24
13:01
06/24/19
13:01
On The Fly
Fly Insider: Seres, Tiffany among week's notable insider transactions »

Welcome to "Fly Insider,"…

MCRB

Seres Therapeutics

$2.99

0.31 (11.57%)

PSEC

Prospect Capital

$6.62

0.02 (0.30%)

SGMS

Scientific Games

$18.30

-0.69 (-3.63%)

FCNCA

First Citizens

$437.76

2.47 (0.57%)

PBF

PBF Energy

$27.64

-0.825 (-2.90%)

GIII

G-III Apparel

$27.96

0.04 (0.14%)

TIF

Tiffany

$92.98

-0.66 (-0.70%)

NVDA

Nvidia

$153.37

1.63 (1.07%)

ZAYO

Zayo Group

$33.00

-0.04 (-0.12%)

WRB

W. R. Berkley

$67.11

0.23 (0.34%)

ZBRA

Zebra Technologies

$201.50

1.35 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 15

    Aug

BCOM

B Communications Ltd.

$1.90

0.05 (2.70%)

12:59
06/24/19
06/24
12:59
06/24/19
12:59
Hot Stocks
B Communications Ltd. says board approves Searchlight transaction »

B Communications Ltd.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$288.53

-5 (-1.70%)

12:55
06/24/19
06/24
12:55
06/24/19
12:55
Options
Anthem put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MNK

Mallinckrodt

$8.57

-0.39 (-4.35%)

12:40
06/24/19
06/24
12:40
06/24/19
12:40
Options
Mallinckrodt call block opens $5M long-dated position 110% above spot »

Mallinckrodt call block…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BZUN

Baozun

$48.07

-1.33 (-2.69%)

12:35
06/24/19
06/24
12:35
06/24/19
12:35
Options
Baozun put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$62.66

-1.1 (-1.73%)

12:25
06/24/19
06/24
12:25
06/24/19
12:25
Conference/Events
Cubic to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

FB

Facebook

$193.26

2.1 (1.10%)

12:23
06/24/19
06/24
12:23
06/24/19
12:23
Periodicals
Facebook's Clegg dismisses calls for break-up, Reuters says »

Facebook's head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

JMIA

Jumia Technologies

$25.42

-0.26 (-1.01%)

12:20
06/24/19
06/24
12:20
06/24/19
12:20
Periodicals
Jumia Food eyes Africa's middle class to boost growth, Reuters says »

Jumia Food, Jumia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$44.83

-1.4 (-3.03%)

12:20
06/24/19
06/24
12:20
06/24/19
12:20
Options
E Trade put seller opens August 40 strike position »

E Trade put seller opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

T

AT&T

$32.59

0.13 (0.40%)

12:18
06/24/19
06/24
12:18
06/24/19
12:18
Hot Stocks
AT&T's WarnerMedia appoints Ann Sarnoff CEO of Warner Bros. »

WarnerMedia CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

FTD

FTD Companies

$0.00

(0.00%)

12:17
06/24/19
06/24
12:17
06/24/19
12:17
Hot Stocks
FTD Companies enters into asset purchase agreement for Personal Creations »

FTD Companies provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/24/19
06/24
12:17
06/24/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/24/19
06/24
12:16
06/24/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$45.94

-3.42 (-6.93%)

, CELG

Celgene

$93.98

-4.94 (-4.99%)

12:15
06/24/19
06/24
12:15
06/24/19
12:15
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are mildly higher…

BMY

Bristol-Myers

$45.94

-3.42 (-6.93%)

CELG

Celgene

$93.98

-4.94 (-4.99%)

ERI

Eldorado Resorts

$45.74

-5.48 (-10.70%)

CZR

Caesars

$11.52

1.53 (15.32%)

PCMI

PCM, Inc.

$34.71

10.36 (42.55%)

NSIT

Insight Enterprises

$57.56

1.37 (2.44%)

KRYS

Krystal Biotech

$37.20

7.92 (27.05%)

SBH

Sally Beauty

$12.94

-1.85 (-12.51%)

AMZN

Amazon.com

$1,909.00

-1.42 (-0.07%)

WAB

Wabtec

$68.53

-4.22 (-5.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 24

    Jun

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 02

    Jul

  • 10

    Jul

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

SRPT

Sarepta

$128.78

-1.13 (-0.87%)

12:15
06/24/19
06/24
12:15
06/24/19
12:15
Options
Sarepta put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ENS

EnerSys

$66.07

0.2997 (0.46%)

12:07
06/24/19
06/24
12:07
06/24/19
12:07
Conference/Events
EnerSys management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

GBT

Global Blood Therapeutics

$64.21

1.2 (1.90%)

12:05
06/24/19
06/24
12:05
06/24/19
12:05
Options
Global Blood Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$37.20

7.92 (27.05%)

12:03
06/24/19
06/24
12:03
06/24/19
12:03
Recommendations
Krystal Biotech analyst commentary at Chardan »

Krystal Biotech price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

CNC

Centene

$55.52

-0.86 (-1.53%)

, WCG

WellCare

$296.08

-3.1 (-1.04%)

12:01
06/24/19
06/24
12:01
06/24/19
12:01
Hot Stocks
Centene, WellCare stockholders approve proposals regarding WellCare acquisition »

Centene Corporation (CNC)…

CNC

Centene

$55.52

-0.86 (-1.53%)

WCG

WellCare

$296.08

-3.1 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

QUAD

Quad/Graphics

$8.16

-0.94 (-10.33%)

12:00
06/24/19
06/24
12:00
06/24/19
12:00
Hot Stocks
Quad/Graphics falls -10.5% »

Quad/Graphics is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.